‘Text/HTML’ of page ‘Tocagen and NRG Oncology to Collaborate on a Phase 2/3 Trial of Toca 511 & Toca FC in Newly Diagnosed Glioblastoma ‘
Tocagen and NRG Oncology to Collaborate on a Phase 2/3 Trial of Toca 511 & Toca FC in Newly Diagnosed Glioblastoma Proposed NRG-BN006 Phase 2/3 trial to begin enrollment in 2019 SAN DIEGO – Nov. 29, 2018 – Tocagen Inc. (Nasdaq: TOCA), a late clinical-stage, cancer-selective gene therapy company and NRG Oncology, a member of […]
Read More